Manchester Capital Management LLC raised its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 0.6% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 17,946 shares of the medical instruments supplier’s stock after buying an additional 100 shares during the period. Becton, Dickinson and comprises about 0.6% of Manchester Capital Management LLC’s investment portfolio, making the stock its 18th biggest holding. Manchester Capital Management LLC’s holdings in Becton, Dickinson and were worth $3,501,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. BlackRock Inc. boosted its position in Becton, Dickinson and by 2,427.8% during the 1st quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock valued at $3,034,470,000 after buying an additional 15,887,611 shares during the period. Vanguard Group Inc. boosted its position in Becton, Dickinson and by 5.3% during the 1st quarter. Vanguard Group Inc. now owns 15,902,168 shares of the medical instruments supplier’s stock valued at $2,917,094,000 after buying an additional 796,034 shares during the period. JPMorgan Chase & Co. boosted its position in Becton, Dickinson and by 6.5% during the 1st quarter. JPMorgan Chase & Co. now owns 3,967,843 shares of the medical instruments supplier’s stock valued at $727,863,000 after buying an additional 242,081 shares during the period. Fundsmith LLP boosted its position in Becton, Dickinson and by 3.2% during the 1st quarter. Fundsmith LLP now owns 2,296,613 shares of the medical instruments supplier’s stock valued at $421,291,000 after buying an additional 71,691 shares during the period. Finally, Geode Capital Management LLC boosted its position in Becton, Dickinson and by 8.4% during the 1st quarter. Geode Capital Management LLC now owns 1,941,743 shares of the medical instruments supplier’s stock valued at $355,653,000 after buying an additional 151,238 shares during the period. 87.12% of the stock is owned by institutional investors and hedge funds.

Several brokerages have weighed in on BDX. Bank of America Corporation reissued a “buy” rating and set a $225.00 price target (up previously from $200.00) on shares of Becton, Dickinson and in a research report on Friday, July 21st. Piper Jaffray Companies reissued a “buy” rating and set a $213.00 price target on shares of Becton, Dickinson and in a research report on Tuesday, September 12th. BidaskClub raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a research report on Monday, August 14th. Zacks Investment Research raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price target for the company in a research report on Monday, July 17th. Finally, Cowen and Company reissued a “buy” rating and set a $230.00 price target on shares of Becton, Dickinson and in a research report on Monday, August 14th. Five investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $200.93.

Becton, Dickinson and Company (NYSE:BDX) opened at 195.00 on Thursday. Becton, Dickinson and Company has a 52 week low of $161.29 and a 52 week high of $206.63. The company has a 50 day moving average of $197.37 and a 200 day moving average of $192.32. The company has a market capitalization of $44.37 billion, a price-to-earnings ratio of 56.47 and a beta of 1.05.

Becton, Dickinson and (NYSE:BDX) last issued its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.44 by $0.02. The firm had revenue of $3.04 billion during the quarter, compared to analyst estimates of $3.06 billion. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The business’s revenue was down 5.1% on a year-over-year basis. During the same period in the previous year, the firm earned $2.35 earnings per share. On average, equities analysts forecast that Becton, Dickinson and Company will post $9.46 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Friday, September 29th. Stockholders of record on Friday, September 8th were paid a dividend of $0.73 per share. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.50%. The ex-dividend date was Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio is currently 83.43%.

WARNING: “Manchester Capital Management LLC Has $3.50 Million Holdings in Becton, Dickinson and Company (BDX)” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/manchester-capital-management-llc-has-3-50-million-holdings-in-becton-dickinson-and-company-bdx/1609278.html.

In related news, insider Thomas E. Polen, Jr. sold 5,971 shares of the company’s stock in a transaction dated Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total value of $1,178,735.11. Following the completion of the sale, the insider now directly owns 12,861 shares of the company’s stock, valued at $2,538,890.01. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Stephen Sichak sold 11,787 shares of the company’s stock in a transaction dated Friday, September 8th. The stock was sold at an average price of $200.46, for a total transaction of $2,362,822.02. Following the completion of the sale, the insider now directly owns 14,038 shares of the company’s stock, valued at $2,814,057.48. The disclosure for this sale can be found here. Insiders have sold 75,904 shares of company stock valued at $15,242,688 over the last three months. Insiders own 1.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.